top of page
Saving Brain Cells.
Changing Lives.
X-tosis is a precision-medicine platform company developing first-in-class mitochondrial therapeutics to prevent neuronal loss.
Transforming Neurodegenerative Disease Treatment with XTS Compounds
X-tosis is advancing first-in-class mitochondrial therapeutics that target the root causes of neurodegeneration. Our VDAC1-modulating compounds are designed to restore mitochondrial function, reduce inflammation, and prevent neuronal death, offering a fundamentally disease-modifying approach to Alzheimer’s disease, Parkinson’s disease, ALS, and related conditions. With precision biomarkers guiding patient selection, treatment, and monitoring, X-tosis is pioneering a platform for next-generation neurodegenerative disease therapies
The Science Behind Our Approach to Stopping Neuronal Death
X-tosis develops first-in-class mitochondrial therapeutics that intervene upstream in the biology of neuronal death. Our compounds modulate VDAC1 to restore mitochondrial function, prevent apoptosis, and protect neurons across neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS. Supported by precision biomarkers and mechanistic insight, our science is redefining what disease-modifying therapy can be.
Subscribe to our mailing list to stay updated.
bottom of page